Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Next Day Mood Is Affected by Ability to Recover From Work.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Kate Middleton and Remission: Oncologists Weigh In
4.
A new device enhances liquid biopsy.
5.
Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.
1.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
2.
The Future of Hemophilia Treatment: Long-Acting Therapies and Gene Editing
3.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
4.
How to Manage Dic with the Right Treatment Approach
5.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge